Dr. Sartor on Sipuleucel-T in mCRPC

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the analysis of African-American patients receiving sipuleucel-T (Provenge) compared with Caucasians with metastatic castration-resistant prostate cancer.

The analysis was focused on African Americans as compared with Caucasians. Unlike many prior studies, there was a positive effect for African-American—treated patients, explains Sartor. This study demonstrated that African Americans see more of a benefit with sipuleucel-T based on the PROCEED registry report.

The study matched 420 Caucasians with 210 African Americans, making a 2:1 match looking at all prostate-specific antigen (PSA) scores, states Sartor. A multivariate analysis was investigated to determine that African Americans would continue to have the effect when other factors, such as hemoglobin and alkaline phosphate were taken into account.